Authors: LEE Y ROGERS JD MENDEL C CONROY JA STEPANAVAGE M MCLOUGHLIN DA OLAH TV

Citation: Y. Lee et al., PHARMACOKINETICS (PK) OF ORAL RIZATRIPTAN (R) IN HEALTHY-MALES AND FEMALES, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 23-23

Authors: SCIBERRAS DG POLVINO WJ GERTZ BJ CHENG HY STEPANAVAGE M WITTREICH J OLAH T EDWARDS M MANT T

Citation: Dg. Sciberras et al., INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HTID AGONIST (VOL 43, PG 49, 1997), British journal of clinical pharmacology, 43(4), 1997, pp. 450-450

Authors: SCIBERRAS DG POLVINO WJ GERTZ BJ CHENG HY STEPANAVAGE M WITTREICH J OLAH T EDWARDS M MANT T

Citation: Dg. Sciberras et al., INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HT1D AGONIST, British journal of clinical pharmacology, 43(1), 1997, pp. 49-54

Authors: BACHMANN K SULLIVAN TJ REESE JH JAUREGUI L MILLER K SCOTT M YEH KC STEPANAVAGE M KING JD SCHWARTZ J

Citation: K. Bachmann et al., CONTROLLED-STUDY OF THE PUTATIVE INTERACTION BETWEEN FAMOTIDINE AND THEOPHYLLINE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY-DISEASE, Journal of clinical pharmacology, 35(5), 1995, pp. 529-535

Authors: POLVINO W SCIBERRAS D GERTZ B CHENG H STEPANAVAGE M WITTREICH J OLAH T EDWARDS M MANT T

Citation: W. Polvino et al., MK-462 - 1ST HUMAN-EXPERIENCE WITH A NOVEL 5-HT1D AGONIST, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 129-129

Authors: NUSSBAUM SR WARRELL RP RUDE R GLUSMAN J BILEZIKIAN JP STEWART AF STEPANAVAGE M SACCO JF AVERBUCH SD GERTZ BJ

Citation: Sr. Nussbaum et al., DOSE-RESPONSE STUDY OF ALENDRONATE SODIUM FOR THE TREATMENT OF CANCER-ASSOCIATED HYPERCALCEMIA, Journal of clinical oncology, 11(8), 1993, pp. 1618-1623